We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use a crossover randomised controlled trial to evaluate your digital health product.
How to use a combination of quantitative and qualitative data to evaluate your digital health product.
How to use an interrupted time series to evaluate your digital health product.
The VDEC clinical evaluation team works to support vaccine and therapeutic development by providing expertise in immunological and functional assays used to support clinical trials (Phase I to IV)
How to use a cost utility analysis to evaluate your digital health product.
This toolkit is for Innovation Passport holders following the Innovative Licensing and Access Pathway (ILAP) and provides activities to support the design and development of medicines.
How to use a randomised controlled trial to evaluate your digital health product.
Guidance for people with symptoms of a respiratory infection including COVID-19, or a positive test result for COVID-19.
Submissions related to human medicines need to be submitted directly to the MHRA.
This guidance identifies common issues with validation and assessment of clinical trial applications and how to avoid them.
Guidance on how to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in the UK.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
How to use a cost consequence analysis to evaluate your digital health product.
The CMA has today published its main concerns following an initial review into the veterinary sector.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).